Jan 24, 2023 / NTS GMT
Presentation
Jan 24, 2023 / NTS GMT
=====================
Corporate Participants
=====================
* Steven Yatomi- Clarke
Prescient Therapeutics - CEO and MD
=====================
Steven Yatomi-Clarke - Prescient Therapeutics - CEO and MD
Firstly, we've got progress across all of our pipeline. We've got the benefit of one of the many benefits of having such a deep and diverse pipeline is that we get progress on many fronts. We only need one of the horses to cross the finish line, but with all of them doing so well at the moment. PTX-100 is our lead candidate of our targeted therapies in the clinic. That data, as we announced recently is unfolding surprisingly well.
To the point that we are considering a registration study and what that might look like. So as that data continues to unfold, we know that the benchmark for what's out there at the moment is here and it looks like we're hitting or exceeding what you would expect from a registrable drug. So incredibly exciting, and we'll be announcing progress as to what that looks
Prescient Therapeutics Ltd Corporate Presentation Transcript
Mar 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers